Glypican-1 targeted nanoplatform for pancreatic ductal adenocarcinoma: interpreting findings Authors: Arman Abroumand Gholami, Djalolidin Mansurov, Tolib Bekmirov Published: 2026 Dear Editor, We read with interest the study by Ren and colleagues, which presents a GPC1‑targeted nanoplatform (GCPIP) integrating chemo‑sonodynamic therapy and real‑time US imaging for pancreatic ductal adenocarcinoma (PDAC) (Ren 2026). The authors are to be commended for developing a multifunctional system with promising in vitro data. However, three conceptual flaws warrant careful consideration before the findings can be interpreted as evidence of a clinically viable strategy. First, the study uses a clinically irrelevant control arm, a straw man comparator. The authors compare their GCPIP with free paclitaxel (PTX) alone. However, paclitaxel as monotherapy has never been a standard of care for PDAC. The current first‑line standards for metastatic PDAC are gemcitabine plus nab‑paclitaxel or FOLFIRINOX (Hoff et al. 2013; Conroy et al. 2025). In the landmark MPACT trial (NEJM 2013), nab‑paclitaxel plus gemcitabine significantly improved overall survival compared with gemcitabine alone (hazard ratio for death, 0.72; P < 0.001), establishing this combination as a global standard (Hoff et al. 2013). ESMO 2025 guidelines recommend FOLFIRINOX and nab‑paclitaxel plus gemcitabine as first‑line options for fit patients (Conroy et al. 2025). Paclitaxel monotherapy is neither recommended nor used in this setting. By choosing a non‑standard, inactive comparator, the study commits a straw man fallacy, demonstrating superiority over an irrelevant control does not establish clinical value. The appropriate comparator should have been gemcitabine‑based therapy (the current backbone of PDAC treatment). Without this comparison, the claim that GCPIP offers a promising strategy to overcome chemoresistance is unsubstantiated. Second, the subcutaneous xenograft model cannot validate active targeting claims for PDAC. The authors attribute the higher tumour uptake of GCPIP to GPC1‑Ab‑mediated active targeting, using a subcutaneous xenograft model. However, this model lacks the pathophysiological features that define human PDAC. A critical review highlighted that pancreatic ductal adenocarcinoma exhibits collapsed vasculatures with relatively high vessel integrity, often accompanied by high pericyte coverage (Qin et al. 2024). These features severely impair nanoparticle delivery via the enhanced permeability and retention (EPR) effect. The same source notes that, conversely, subcutaneous xenografts (e.g., KB‑31) demonstrate pronounced vascular leakiness, characterised by compromised vessel integrity, low pericyte coverage, and round‑like vascular structures. These characteristics facilitate substantial nanoparticle accumulation, precisely the kind of enhanced uptake reported in the present study. In other words, the very model chosen by the authors may artificially inflate nanoparticle accumulation due to exaggerated vascular leakiness, thereby creating a false impression of active targeting efficacy. Subcutaneous models do not recapitulate the dense desmoplastic stroma, elevated interstitial fluid pressure, or vascular compression that define human PDAC and severely limit drug delivery. A growing consensus in the field holds that orthotopic models, which preserve the native tumour microenvironment, are essential for evaluating therapies that depend on tissue penetration and stromal interactions (Qin et al. 2024). Thus, the claim of GPC1‑mediated active targeting is unsubstantiated without validation in an orthotopic PDAC model that preserves the native stromal architecture and vascular barriers. Third, the authors rely on GPC1 as a tumour‑specific antigen to achieve active targeting. However, a large‑scale study of 186 PDAC patients demonstrated that while GPC1 is barely detectable in normal pancreas, it is expressed in 59.7% of PDAC tissues and, critically, in 63.6% of early‑stage (stage I) tumours (Lu et al. 2017). This confirms GPC1 as a useful diagnostic marker but does not establish tumour‑restricted specificity. More importantly, the authors provide no data on GPC1 expression in normal mouse tissues relevant to the subcutaneous model. The Human Protein Atlas database shows that GPC1 protein is expressed in multiple normal human tissues, including subsets of renal tubules, endothelial cells, intestinal glands, astrocytes, and squamous epithelium. Consequently, the observed accumulation of GCPIP in subcutaneous tumours cannot be unequivocally attributed to GPC1‑mediated active targeting. Without quantitative biodistribution data comparing GPC1‑positive versus GPC1‑negative tumours, or evidence of minimal uptake in normal tissues that express endogenous GPC1 (e.g., kidney, intestine), the claim of active targeting remains unsubstantiated. Enhanced tumour uptake could equally reflect passive EPR effects, which are known to be pronounced in leaky subcutaneous xenografts, rather than true antigen‑specific recognition. Thus, the conclusion that GCPIP achieves GPC1‑specific active targeting is premature without appropriate specificity controls. Acknowledgements N/A. Author contributions A.A.G. conceptualized the commentary, performed the critical analysis of the original article, and wrote the main manuscript text. D.M. and T.B. contributed to the literature search and methodological review, and participated in manuscript revision. All authors reviewed and approved the final version of the manuscript. Funding None. Data availability No datasets were generated or analysed during the current study. Declarations Conflict of interest The authors declare no competing interests. Ethical approval Not applicable. Consent for publication All authors approved the final manuscript and the submission to this journal. Informed consent Not applicable. Patient consent N/A. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.